Human CD4+ T cell recent thymic emigrants are identified by protein tyrosine kinase 7 and have reduced immune function
CD4(+) recent thymic emigrants (RTEs) comprise a clinically and immunologically important T cell population that indicates thymic output and that is essential for maintaining a diverse alphabeta-T cell receptor (TCR) repertoire of the naive CD4(+) T cell compartment. However, their frequency and fun...
Saved in:
Published in | The Journal of experimental medicine Vol. 206; no. 2; pp. 275 - 285 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The Rockefeller University Press
16.02.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | CD4(+) recent thymic emigrants (RTEs) comprise a clinically and immunologically important T cell population that indicates thymic output and that is essential for maintaining a diverse alphabeta-T cell receptor (TCR) repertoire of the naive CD4(+) T cell compartment. However, their frequency and function are poorly understood because no known surface markers distinguish them from older non-RTE naive CD4(+) T cells. We demonstrate that protein tyrosine kinase 7 (PTK7) is a novel marker for human CD4(+) RTEs. Consistent with their recent thymic origin, human PTK7(+) RTEs contained higher levels of signal joint TCR gene excision circles and were more responsive to interleukin (IL)-7 compared with PTK7(-) naive CD4(+) T cells, and rapidly decreased after complete thymectomy. Importantly, CD4(+) RTEs proliferated less and produced less IL-2 and interferon-gamma than PTK7(-) naive CD4(+) T cells after alphabeta-TCR/CD3 and CD28 engagement. This immaturity in CD4(+) RTE effector function may contribute to the reduced CD4(+) T cell immunity observed in contexts in which CD4(+) RTEs predominate, such as in the fetus and neonate or after immune reconstitution. The ability to identify viable CD4(+) RTEs by PTK7 staining should be useful for monitoring thymic output in both healthy individuals and in patients with genetic or acquired CD4(+) T cell immunodeficiencies. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 D. Ross's present address is Applied Genomics, Inc., Burlingame, CA 94010. M. Tessier-Lavigne's present address is Genentech, Inc., San Francisco, CA 94080. L.-S. Lu's present address is Medarex, Inc., Milpitas, CA 94043. X. Lu's present address is Department of Cell Biology, University of Virginia, Charlottesville, VA 22908. |
ISSN: | 0022-1007 1540-9538 |
DOI: | 10.1084/jem.20080996 |